Unlike what was observed when DLBCL-derived EVs were directly incubated with T-cells and induced their inhibition by secreting potent immunosuppressive molecules [104], DLBCL-derived small EVs carrying tumor-specific antigens pulsed into DCs reactivated the antigen-presenting capacity of DCs, resulting in a cross-priming of CD8+ T-cells and a potent CTL-dependent lysis of syngeneic and allogeneic tumors [117]. The gene discussed is CD8A; the disease is neoplasm.